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Abstract
 Objective—To evaluate whether minimally invasive surgery for endometrial cancer is 
independently associated with a decreased odds of venous thromboembolism compared with open 
surgery.
 Methods—We performed a secondary analysis cohort study of prospectively collected quality 
improvement data and examined patients undergoing hysterectomy for endometrial cancer from 
2008–2013 recorded in the National Surgical Quality Improvement Program database. Patients 
undergoing minimally invasive (laparoscopic or robotic) versus open surgery were compared with 
respect to 30-day postoperative venous thromboembolism. Demographic and procedure variables 
were examined as potential confounders. Data regarding receipt of perioperative venous 
thromboembolism prophylaxis was not available. Bivariable tests and logistic regression were used 
for analysis.
 Results—Of 9,948 patients who underwent hysterectomy for the treatment of endometrial 
cancer, 61.9% underwent minimally invasive surgery and 38.1% underwent open surgery. Patients 
undergoing minimally invasive surgery had a lower venous thromboembolism incidence (0.7%, 
n=47) than open surgery patients (2.2%, n=80) (p<0.001). In a multivariate model adjusting for 
age, BMI, race, operative time, Charlson comorbidity score, and surgical complexity, minimally 
invasive surgery remained associated with decreased odds of venous thromboembolism (aOR 0.36, 
95% CI 0.24–0.53) compared with open surgery.
 Conclusions—Minimally invasive surgery for the treatment of endometrial cancer is 
independently associated with decreased odds of venous thromboembolism compared with open 
surgery.
PRECIS
Minimally invasive surgery for endometrial cancer is associated with a lower incidence of venous 
thromboembolism compared with open surgery.
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 INTRODUCTION
Minimally invasive surgery, both laparoscopic and robotic, is increasingly being used to treat 
endometrial cancer (1, 2). Many have documented that gynecologic oncology minimally 
invasive surgery is associated with a low incidence of venous thromboembolism, ranging 
from 0.4–2.2% (3–7). However, with the exception of one study, all have been single 
institution retrospective series with less than 10 venous thromboembolism events. 
Additionally, all studies have not had a comparative open surgery group. Patients who 
undergo open surgery may have a higher prevalence of venous thromboembolism risk 
factors, such as age, obesity and other comorbid conditions. Thus, a direct comparison of 
incidence without adjustment for these factors is insufficient to conclude that patients 
undergoing minimally invasive surgery are lower risk.
Given the low incidence of venous thromboembolism in gynecologic oncology minimally 
invasive surgery, some have advocated that these patients are low risk enough to not require 
prophylaxis (8). However, endometrial cancer is associated with other risk factors for venous 
thromboembolism, such as age, operative time, obesity and medical comorbidities. Given 
the high prevalence of risk factors for venous thromboembolism among endometrial cancer 
patients, there may be minimally invasive surgery patients that are at sufficient risk to 
warrant prophylaxis.
Our primary objective was to evaluate whether minimally invasive surgery for the treatment 
of endometrial cancer is independently associated with a decreased odds of venous 
thromboembolism compared with open surgery. Our secondary objective was to develop a 
risk assessment score to predict venous thromboembolism in the minimally invasive surgery 
endometrial cancer patient.
 MATERIALS AND METHODS
This was a secondary analysis cohort study of prospectively collected surgical quality data. 
The study population was patients who underwent surgery, including a hysterectomy, for 
endometrial cancer between 2008 and 2013 identified from the American College of 
Surgeons National Surgical Quality Improvement Program Database using International 
Classification of Diseases, Ninth Revision codes and Current Procedural Terminology (CPT) 
codes. The Institutional Review Board at the University of North Carolina at Chapel Hill 
reviewed this study and declared it exempt from formal review as it does not constitute 
human subjects research.
The National Surgical Quality Improvement Program database is a national surgical quality 
database. Trained clinical reviewers prospectively collect preoperative variables and post-
operative outcomes for each individual procedure for 30 days following surgery. Periodic 
auditing, including for data points occurring after hospital discharge, ensures high quality 
data specifically for post-discharge complications (9). Details of methods of data collection 
and reliability have been previously reported (10).
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Our primary outcome was venous thromboembolism (pulmonary embolism or a deep vein 
thrombosis) diagnosed within 30-days postoperatively (11). Our exposure was route of 
surgery, either minimally invasive surgery (total laparoscopic, laparoscopically assisted 
vaginal or robotic hysterectomy) or open surgery (total abdominal hysterectomy). Of note, 
CPT codes for laparoscopic-assisted and robotic-assisted hysterectomy are the same and so 
we were unable to distinguish between these two surgical approaches.
Demographic, medical and operative characteristics were evaluated as potential 
confounders. Medical factors included body mass index (BMI), smoking, diabetes, 
hypertension and comorbid conditions measured by the Charlson comorbidity index which 
was calculated for as previously described (12, 13). Operative factors included total 
operative time, lymphadenectomy (pelvic or para-aortic) and surgical complexity, defined as 
the sum of the work relative value units for all CPT codes listed for a given procedure (14). 
Total relative value units are a commonly used and accepted measure of surgical complexity 
(15–17). There were no changes in the assigned work relative value units for all included 
CPT codes during the study period. Potential confounders not available for evaluation were 
cancer specific variables, such as stage, and data regarding receipt of perioperative 
thromboembolism prophylaxis.
We initially examined the characteristics of the sample using descriptive statistics. To 
identify potential confounders, we examined whether independent variables were unequally 
distributed by route of surgery. Bivariable comparisons were performed using a 2-sample t-
test and a Mann Whitney U test for continuous variables, depending on the normality of the 
distribution, and Pearson’s chi-square test for categorical variables. We fit a logistic 
regression model, using an analysis of covariance strategy, to estimate the odds ratio for 
venous thromboembolism by route of surgery, adjusted for confounders.
To construct our minimally invasive surgery venous thromboembolism risk score, we limited 
our analysis only to minimally invasive surgery patients as defined above. A logistic 
regression model was used to identify potential predictors of venous thromboembolism. 
Potential predictors and binary cut points were selected based on previously literature (4, 6). 
The calibration of this risk score was tested using the goodness of fit test and the 
discrimination of the model was assessed using the area under the receiver operating 
characteristic curve. All analyses were performed using SPSS version 20.0 (IBM Corp, 
Armonk, NY).
 RESULTS
We identified 9,948 patients with the demographic and operative characteristics as listed in 
Table 1. The majority of patients (61.9%) underwent minimally invasive surgery and 38.1% 
underwent open surgery. Patients who underwent minimally invasive surgery were 
significantly different than those who underwent open surgery in many ways (Table 2). 
Patients who underwent minimally invasive surgery were younger and more likely to be 
White compared to open surgery patients. Patients who underwent minimally invasive 
surgery were also healthier with lower rates of hypertension, smoking, diabetes, and lower 
Charlson comorbidity scores. Minimally invasive surgery cases were also longer.
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Patients undergoing open surgery had a venous thromboembolism incidence of 2.2% 
whereas the incidence was 0.7% in minimally invasive surgery patients (p<0.001). Mean 
time to venous thromboembolism diagnosis was 10.5±8.8 days in the minimally invasive 
surgery group and 13.6±9.3 days in the open group (p=0.07). Minimally invasive surgery 
patients with venous thromboembolism were more likely to have their venous 
thromboembolism diagnosed after hospital discharge compared with open surgery patients 
(72.7% v. 42.7%, p=0.001). Older age, race, longer operative time, higher work relative 
value unit, lymphadenectomy, and higher Charlson co-morbidity score were all associated 
with venous thromboembolism (Table 3). In a logistic regression model adjusting for the 
confounders age, race, BMI, operating room time, Charlson comorbidity score and surgical 
complexity, minimally invasive surgery remained associated with decreased odds of venous 
thromboembolism compared to open surgery (aOR 0.36, 95% CI 0.24–0.53).
We constructed another logistic regression model among only the minimally invasive 
surgery patients to identify predictors of venous thromboembolism (Table 4). Age, BMI, and 
operative time were all associated with venous thromboembolism. The discrimination of the 
model was fair with an area under the receiver operating characteristic curve of 0.72 (95%CI 
0.65–0.79, p<0.001).
A risk score was calculated for each patient and the incidence of venous thromboembolism 
for each score was calculated (Table 5). The relative risk of venous thromboembolism 
increased for each 2 points above the referent risk score group. If a binary score is created 
using a cut point of greater than 2, patients with a score of 4–8 have 7.8 times the risk of 
venous thromboembolism compared to patients with a score of 0–2. Using this cut point 
(>2), the sensitivity of the score is 95.6% and specificity is 27.6% while the positive 
predictive value is 0.8% and the negative predictive value is 99.9%.
 DISCUSSION
Our results agree with previous studies: the incidence of venous thromboembolism among 
women undergoing minimally invasive surgery for gynecologic malignancies is low (3–6, 
18). Additionally, the incidence depends heavily on the route of surgery. Minimally invasive 
surgery patients have one-third the risk compared to open surgery patients. This relationship 
persisted even after adjustment for age, race, operative time, surgical complexity and patient 
comorbidities. Currently, the American College of Chest Physicians and the American 
College of Obstetricians and Gynecologists do not recommend that thromboembolism 
prophylaxis differ for minimally invasive versus open surgery (19–21). We have provided 
evidence that open surgery is an independent predictive factor and thus, open surgery 
patients likely require more prophylaxis than minimally invasive surgery patients.
Age, BMI, and operative time were all associated with venous thromboembolism in a 
multivariable model among minimally invasive surgery patients. The identification of these 
as significant risk factors for minimally invasive surgery patients agrees with a previous 
study that found more blood loss, higher BMI and longer operative time were all associated 
with venous thromboembolism (6). However, this study only included seven 
thromboembolism events and only used bivariable tests to examine the relationship. 
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Therefore, our confirmation of their findings in a larger cohort and use of a multivariable 
model to quantify the relative independent contribution of each factor is an important 
addition to the literature.
We developed a model to predict venous thromboembolism among minimally invasive 
surgery endometrial cancer patients. If validated in an additional population, surgeons could 
use this model to guide prophylaxis. Patients with a score of >2 have 7.8 times the risk of 
venous thromboembolism compared to those with a score of 0 or 2. This cut point 
maximizes negative predictive value and sensitivity which is desirable in venous 
thromboembolism where the use of prophylaxis is low risk and the consequences of a 
thromboembolism event are great. Using this cut point, we were able to identify 2,184 
patients or 35% of the minimally invasive surgery population that have a significantly lower 
and low absolute risk of venous thromboembolism. Rather than not using any prophylaxis 
for all minimally invasive surgery cancer patients, as has been advocated (8), this score 
could allow us to identify lower risk patients and selectively use less prophylaxis, such as 
mechanical prophylaxis alone, for them.
Minimally invasive surgery patients were more likely to have their venous thromboembolism 
diagnosed after discharge compared with open surgery patients. Current recommendations 
are extended duration prophylaxis of 28 days after abdominal or pelvic cancer surgery (19, 
22). Given the low incidence of venous thromboembolism in minimally invasive 
gynecologic oncology surgery, many do not use extended prophylaxis (23). However, a 
recent study of minimally invasive surgery colorectal cancer patients found a 10-fold 
decrease in venous thromboembolism incidence with 28-day prophylaxis compared to 1-
week prophylaxis (24). Although extended duration prophylaxis for all minimally invasive 
gynecologic oncology surgery patients is likely unnecessary, its use may be indicated for a 
small group at the highest risk.
Strengths of this study include a large population to study a rare outcome and an open 
surgery comparator group, which allows adjustment of confounding factors and 
quantification of the effect of route of surgery. Additionally, data collection methods in our 
data source have been found to be reliable and accurate (10) and are robust in detecting 
postoperative complications, particularly those that occur after hospital discharge, compared 
to claims-based data sources (9). Finally, this data source has been used to study venous 
thromboembolism in many surgical disciplines and was the data source for the highly cited 
validation of the Caprini score (25–29).
Limitations include a lack of data regarding use of mechanical or pharmacologic 
prophylaxis. Although, it is likely that as cancer patients undergoing surgery, nearly all 
patients received some form of prophylaxis as per the Surgical Care Improvement 
Guidelines. As patients likely received some prophylaxis, but which type is unknown, we 
cannot comment on the ability of prophylaxis to further decrease venous thromboembolism 
incidence, and thus, our recommendations for prophylaxis should be interpreted with 
caution. We also did not have information regarding personal or family history of venous 
thromboembolism, and therefore, these patients should be considered high risk independent 
of route of surgery or the absence of other risk factors presented here. Additionally, our 
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predictive model was developed in this cohort and must be validated in an additional 
population before it can be used clinically. Despite these limitations, our data provides 
evidence that the incidence of venous thromboembolism after surgery for endometrial cancer 
is independently associated with the route of surgery.
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Table 1
Demographic and Operative Characteristics
Characteristics N=9,948
Age (years) 63 (56–70)
BMI (kg/m2) 32.9 (27.1–40.2)
Race
  White 7797 (78.4)
  Black 789 (7.9)
  Asian 353 (3.5)
  Alaska/American native 80 (0.8)
  Unknown 929 (9.3)
Smoking 907 (9.1)
Diabetes 2124 (21.4)
Hypertension 5654 (56.8)
Charlson comorbidity index
  0 7246 (72.8)
  1 2143 (21.5)
  2 367 (3.7)
  3+ 192 (1.9)
Lymphadenectomy 5620 (56.5)
Length of stay (days) 2 (1–3)
Operating time (min) 157 (116–210)
Surgical complexity (wRVU) 30.9 (17.7–34.6)
Data is presented as n(%) for categorical variables and median (interquartile range) for continuous variables.
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Table 2
Association between patient factors and surgical approach
Characteristics Open surgery
(n=3788)
MIS
(n=6160)
p value
Age (years) 63.5 (±11.6) 62.7 (±10.9) 0.0011
BMI (kg/m2) 34.8 (±10.2) 34.4 (±9.8) 0.0261
Race <0.0012
  White 2749 (72.6) 5048 (81.9)
  Black 432 (11.4) 357 (5.8)
  Asian 119 (3.1) 234 (3.8)
  Other 29 (0.8) 51 (0.8)
  Unknown 459 (12.1) 470 (7.6)
Smoking 384 (10.1) 523 (8.5) 0.0062
Diabetes 886 (23.4) 1238 (20.1) <0.0012
Hypertension 2272 (60.0) 3382 (54.9) <0.0012
Charlson comorbidity
index
<0.0012
  0 2537 (67.0) 4709 (76.4)
  1 859 (22.7) 1284 (20.8)
  2 238 (6.3) 129 (2.1)
  3+ 154 (4.1) 38 (0.6)
Lymphadenectomy 3549 (57.6) 2071 (54.7) 0.0042
Length of stay (days) 3 (3–5) 1 (1-1) <0.0013
Operating time (min) 143 (104–196) 165 (124–219) <0.0013
Surgical complexity
(wRVU)
30.8 (21.1–37.1) 31.6 (17.7–34.6) 0.303
1
T-test,
2Chi-square test,
3
Mann Whitney U test.
Data is presented as mean (SD) for continuous variables that are normally distributed and median (interquartile range) for continuous variables that 
are non-normally distributed.
Data is presented as n(%) for categorical variables.
MIS – minimally invasive surgery; wRVU – work relative value unit
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Table 3
Association between patient factors and venous thromboembolism
Characteristics No VTE
(n=9821)
VTE
(n=127)
p value
Age (years) 62.9 (±11.2) 65.6 (±10.6) 0.0071
BMI (kg/m2) 34.5 (±9.9) 35.7 (±9.9) 0.171
Race 0.022
  White 7700 (78.4) 97 (76.4)
  Black 772 (7.9) 17 (13.4)
  Asian 351 (3.6) 2 (1.6)
  Other 77 (0.8) 3 (2.4)
  Unknown 921 (9.4) 8 (6.3)
Smoking 898 (9.1) 9 (7.1) 0.422
Diabetes 2096 (21.3) 28 (22.0) 0.852
Hypertension 5579 (56.8) 75 (59.1) 0.612
Charlson comorbidity
index
<0.0012
  0 7161 (72.9) 85 (66.9)
  1 2119 (21.6) 24 (18.9)
  2 359 (3.7) 8 (6.3)
  3+ 182 (1.9) 10 (7.9)
Lymphadenectomy 5536 (56.4) 84 (66.1) 0.032
Length of stay (days) 2 (1–3) 5 (3–9) <0.0013
Operating time (min) 157 (116–210) 186 (121–265) <0.0013
Surgical complexity
(wRVU)
30.9 (17.7–34.6) 31.0 (23.1–42.8) 0.023
1
T-test,
2Chi-square test,
3
Mann Whitney U test.
Data is presented as mean (SD) for continuous variables that are normally distributed and median (interquartile range) for continuous variables that 
are non-normally distributed.
Data is presented as n(%) for categorical variables.
VTE – venous thromboembolism
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